EUVIMEDEUVIMED entdecken
Kohortenstudie

Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: A population‐based cohort study

Adam S Faye iD, Kristine H Allin, Gry Juul Poulsen, Tine Jess

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.70034 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Adam S Faye und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, NYU Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Primary Prevention, Inflammatory Bowel Diseases. Die Arbeit nennt 32 Literaturangaben. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Beyond genetics, environmental factors may contribute to the rising incidence of inflammatory bowel disease (IBD). Statins, widely used for cardiovascular risk reduction, also have anti‐inflammatory properties and have been hypothesized to reduce IBD risk, though data are limited. We prospectively assessed the association between statin use and risk of developing IBD among individuals eligible for statin therapy for primary prevention of cardiovascular disease.

Methods

Using a prospective new user design within the Danish National Registries, we identified a nationwide cohort of individuals aged ≥40 years from 2008 to 2022 eligible for statin therapy for primary cardiovascular prevention. Statin users were matched 1:5 to nonusers on age, sex, calendar year, and cardiovascular risk factors. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for incident IBD.

Results

We identified 110,961 statin users and 554,805 matched nonusers. Statin use was associated with a reduced risk of IBD (aHR 0.84, 95% CI 0.72–0.97), with subgroup analyses showing similar reductions for Crohn's disease (aHR 0.84, 95% CI 0.65–1.09) and ulcerative colitis (aHR 0.83, 95% CI 0.69–1.00). This corresponds to a number needed to treat of 2881 to prevent one additional IBD case over 5 years of statin treatment. Findings remained consistent when censoring individuals at statin discontinuation.

Conclusion

In this nationwide prospective study, statin use among individuals eligible for primary cardiovascular prevention was associated with a lower risk of developing IBD. These findings suggest a potential additional benefit of statins and support further research into their role in IBD prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesPrimary PreventionInflammatory Bowel DiseasesHumansMaleFemaleMiddle AgedIncidenceDenmarkAdultProspective StudiesAgedRegistriesProportional Hazards ModelsRisk Factors

Stichwörter der Autor:innen

Crohn's diseaseinflammatory bowel diseasestatinulcerative colitis

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Division of Gastroenterology, NYU Grossman School of Medicine, New York, New York, USA.
  • PREDICT, Center for Molecular Prediction of Inflammatory Bowel Disease, Faculty of Medicine, Aalborg University, Copenhagen, Denmark.
  • Department of Gastroenterology & Hepatology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Adam S Faye

Förderung

  • NIA NIH HHS

Zitieren

APA

Faye, A. S., Allin, K. H., Poulsen, G. J., & Jess, T. (2025). Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: A population‐based cohort study. Journal of Internal Medicine. https://doi.org/10.1111/joim.70034

Vancouver

Faye AS, Allin KH, Poulsen GJ, Jess T. Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: A population‐based cohort study. Journal of Internal Medicine. 2025. doi:10.1111/joim.70034

BibTeX
@article{Faye2025,
  author = {Faye, Adam S and Allin, Kristine H and Poulsen, Gry Juul and Jess, Tine},
  title = {Statin use for primary prevention of cardiovascular disease reduces the risk of incident IBD: A population‐based cohort study},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.70034}
}
Kostenlos starten →